SCHEMBL7183528

SCHEMBL7183528

N#Cc1ccc2c(c1)[nH]c(=O)n2-c1ccc2nc[nH]c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 1/20 0.56
TNKS2 Q9H2K2 1/20 0.44
MAP3K11 Q16584 2/20 0.41
LRRK2 Q5S007 1/20 0.41
QPCT Q16769 5/20 0.41
GABRP O00591 2/20 0.41
GABRD O14764 2/20 0.41
GABRA1 P14867 2/20 0.41
GABRB1 P18505 2/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRA5 P31644 2/20 0.41
GABRA3 P34903 2/20 0.41
GABRA2 P47869 2/20 0.41
GABRB2 P47870 2/20 0.41
GABRA4 P48169 2/20 0.41
GABRE P78334 2/20 0.41
GABRA6 Q16445 2/20 0.41
GABRG1 Q8N1C3 2/20 0.41
GABRG3 Q99928 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183522 0.92 MAT2A (0.47) MAT2ATNKS2LRRK2GABRPGABRD
SCHEMBL7190963 0.83 MAT2A (0.47) MAT2ATNKS2MAP3K11QPCTIDO1
SCHEMBL11134 0.78 PRKCI (0.53) ADORA2AHSD11B1
SCHEMBL29424823 0.78 PRKCI (0.53) ADORA2AHSD11B1
Hydrochloric Acid SCHEMBL3671411 0.76 KDM4E (0.55) ADORA2AHSD11B1
SCHEMBL27252266 0.76 TNKS2 (0.50) MAT2ATNKS2LRRK2GABRPGABRD
SCHEMBL7190954 0.76 MAP3K11 (0.39) MAT2ATNKS2MAP3K11LRRK2QPCT
SCHEMBL31435021 0.76 MEN1 (0.62) MAT2ATNKS2LRRK2MEN1LMNA
SCHEMBL20302464 0.73 L3MBTL1 (0.46) TNKS2MEN1LMNAKMT2AL3MBTL1
SCHEMBL7190679 0.71 MAPT (0.53) MAT2AQPCTMEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed